Wednesday, June 29, 2022

Nutra Pharma Corp. (OTCMKTS:NPHC) Makes A Splash

Nutra Pharma Corp. (OTCMKTS:NPHC) jumped in activity and created some waves this past week. NPHC is a biotech company that pursues viral and neurological disease treatment through innovative methods. Currently, NPHC is developing drugs to treat HIV and Multiple Sclerosis as well as pain treatment drugs: Nyloxin® and Pet Pain-Away™ (development already completed). The company’s discovery arm, ReceptoPharm, has two leading products: RPI-MN and RPI-78M.
RPI-MN stops the entry of numerous viruses that are known to cause severe neurological damage in such diseases as encephalitis and HIV. It is being developed first for the treatment of HIV. RPI-78M is being advanced for the management of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS).
Nutra Pharma Corp. (OTCMKTS:NPHC) is founded by an experienced team that is looking to combine biopharmaceuticals and nutrition. The company’s founder has knowledge of using animal venom and toxins to fight disease. NPHC is now using cobra venom as a suitable therapy option.
Find out when $NPHC stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Here is the company’s CEO, Rik Deitsch, on the product and company: “These are clinically proven, all-natural products that are available today to deal with pain and inflammation in people and their pets.” NPHC takes the snake venom and turns the liquid into a powder that they say is non-addictive and can combat the country’s opioid epidemic. In addition, pet pain relievers are few and far between.
Treating pain in another way and offering a more natural option might appeal to customers in certain demographics. Furthermore, the company just launched Luxury Feet; an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos.
“Women who chronically wear high heels are prone to a variety of foot problems, including pain, bunions, hammer toe and Plantar fasciitis,” commented Rik J Deitsch, CEO of Nutra Pharma. “We know that women spend upwards of $600 for a pair of shoes and certainly would like to wear them without fear of pain,” he continued. “Luxury Feet is a new product that can be used safely every day. We know that this product can prevent or treat the pain and inflammation caused by your favorite footwear,” he concluded.
Luxury Feet is an over-the-counter (OTC) homeopathic pain reliever that relies on natural cobra venom’s ability to alleviate pain and inflammation. The product is designed specifically to treat foot and ankle pain in women that can be caused by wearing high heels, pumps or stiletto shoes. Luxury Feet is available as a topical roll-on gel that can be used every day for the prevention and treatment of foot and ankle pain.
Nutra Pharma Corp. (OTCMKTS:NPHC) has some intriguing pain-relieving options and they are targeting some interesting sectors to offer therapy options. This is a specialist and niche company, but the market is surely big enough to provide value here. Plus, these drugs are over the counter and two options are already available with expansion plans in the works. The company is carrying a market cap of $472,755k with 382.37 million shares outstanding. NPHC is now trading up 75% and we will be watching to see where it goes next. For continuing coverage on shares of $NPHC stock, as well as our other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles